三個皮匠報告
政策庫
new
付費
搜索

圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）-行業數據

圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）
近幾年實體瘤領域中 ADC、多抗以及細胞與基因治療藥物臨床啟動的數量明顯增加，代表近幾年的熱門技術類型。
行業數據 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?37KB 圖片尺寸：1748*775
同報告圖片
 / 24
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第1頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第2頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第3頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第4頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第5頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第6頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第7頁
fCBEZXRhaWxlZCBtb2RhbGl0eSB8IERlYWxzIHwgU3VtIG9mIHVwZnJvbnQgcGF5bWVudHMgKFVTJCkgfAp8LS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwKfCBTbWFsbCBtb2xlY3VsZSAgICAgfCAxMiAgICB8IDEuODEgYmlsbGlvbiAgICAgICAgICAgICAgICAgICB8CnwgbUFiICAgICAgICAgICAgICAgIHwgMTEgICAgfCAxLjEyIGJpbGxpb24gICAgICAgICAgICAgICAgICAgfAp8IEFEQyAgICAgICAgICAgICAgICB8IDEwICAgIHwgMi4xNSBiaWxsaW9uICAgICAgICAgICAgICAgICAgIHwKfCBULWNlbGwgZW5nYWdlciAgICAgfCA2ICAgICB8IDEuMTMgYmlsbGlvbiAgICAgICAgICAgICAgICAgICB8CnwgQmktL211bHRpLXNwZWNpZmljIG1BYiB8IDUgICAgIHwgMi4zIGJpbGxpb24gICAgICAgICAgICAgICAgICAgIHwKfCBPdGhlciAgICAgICAgICAgICAgfCA0ICAgICB8IDAuNDMgYmlsbGlvbiAgICAgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupA6IE5hdHVyZSBSZXZpZXdzLCDlhbTkuJror4HliLjnu4/mtY7kuI7ph5Hono3noJTnqbbpmaLmlbTnkIY=
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第8頁
fCBBc3NldCBzdGFnZSB8IERlYWxzIHwgU3VtIG9mIHVwZnJvbnQgcGF5bWVudHMgKFVTJCkgfAp8LS0tfC0tLXwtLS18IAp8IFByZWNsaW5pY2FsIHwgMjAgKDQyJSkgfCAkOC40IGJpbGxpb24gKDU4JSkgfAp8IFBoYXNlIEkgfCAxNCAoMjklKSB8ICQ0Ljg0IGJpbGxpb24gKDM0JSkgfAp8IFBoYXNlIElJIHwgNSAoMTAlKSB8ICQxLjEgYmlsbGlvbiAoMTMlKSB8CnwgUGhhc2UgSUlJIHwgNSAoMTAlKSB8ICQxLjY3IGJpbGxpb24gKDIwJSkgfAp8IE1hcmtldGVkIHwgMiAoNCUpIHwgJDAuNjEgYmlsbGlvbiAoNyUpIHwKfCBOb3QgZGlzY2xvc2VkIHwgMSAoMiUpIHwgJDAuMDcgYmlsbGlvbiAoMSUpIHwKfCBQcmUtcmVnaXN0cmF0aW9uIHwgLSB8IC0gfAoK6LWE5paZ5p2l5rqQOiBOYXR1cmUgUmV2aWV3cywg5YW05Lia6K+B5Yi457uP5rWO5LiO6YeR6J6N56CU56m26Zmi5pW055CG
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第9頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第10頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第11頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第12頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第13頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第14頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第15頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第16頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第17頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第18頁
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第19頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第20頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第21頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第22頁
fCDliIbnsbsgICAgICAgICB8IOS4tOW6iuWFpee7hOmAn+W6pu+8iOS6ui/kuK3lv4Mv5pyI77yJIHwKfC0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IFBELTEgICAgICAgICB8IDAuMy0wLjUgICAgICAgICAgICAgICAgICB8CnwgICAgICAgICAgICAgIHwgMC45ICAgICAgICAgICAgICAgICAgICAgIHwKfCBHTFAtMSAgICAgICAgfCB+MiAgICAgICAgICAgICAgICAgICAgICAgfAp8ICAgICAgICAgICAgICB8IH4xMCAgICAgICAgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrpuqbogq/plKHvvIzlhbTkuJror4HliLjnu4/mtY7kuI7ph5Hono3noJTnqbbpmaLmlbTnkIY=
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第23頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第24頁
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
圖11、2014-2023年實體瘤領域1-3期臨床啟動的數量（按藥物類型區分）_第25頁
fCDml6XmnJ8gICAgICAgfCDpg6jpl6ggICB8IOaUv+etluWPiuS6i+S7tiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCDmhI/kuYkgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwtLS0tLS0tLS0tLS18LS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tfAp8IDIwMTUvOC85ICAgfCDlm73liqHpmaIgfCDjgIrlhbPkuo7mlLnpnanoja/lk4HljLvnlpflmajmorDlrqHor4TlrqHmibnliLbluqbnmoTmhI/op4HjgIsgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCDop6PlhrPnp6/ljovvvIzliqDlv6vlrqHor4TlrqHmibnvvIzliJvmlrDoja/lrprkuYnku47igJzkuK3lm73mlrDigJ3ovazlj5jkuLrigJzlhajnkIPmlrDigJ0gICAgICAgICB8CnwgMjAxNi8yLzYgICB8IOWbveWKoemZoiB8IOOAiuWFs+S6juW8gOWxleS7v+WItuiNr+i0qOmHj+WSjOeWl+aViOS4gOiHtOaAp+ivhOS7t+eahOaEj+ingeOAiyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCDkuLrluKbph4/ph4fotK3mj5Dkvpvor4Tku7fln7rnoYAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAxNi81LzI2ICB8IOWbveWKoemZoiB8IOOAiuWFs+S6juWNsOWPkeS4iuW4guiuuOWPr+aMgeacieS6uuWItuW6puivleeCueaWueahiOeahOmAmuefpeOAiyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCDosIPliqjnoJTlj5HmnLrmnoTlkoznp5HnoJTkurrlkZjliJvmlrDnp6/mnoHmgKcgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMTcvNiAgICAgfCDoja/nm5HlsYAgfCDkuK3lm73liqDlhaUgSUNIICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IOebkeeuoeS9k+ezu+WwhuabtOaOpei/keWbvemZheagh+WHhiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAxNy8xMC84ICB8IOWbveWKoemZoiB8IOOAiuWFs+S6jua3seWMluWuoeivhOWuoeaJueWItuW6puaUuemdqem8k+WKseiNr+WTgeWMu+eWl+WZqOaisOWIm+aWsOeahOaEj+ingeOAiyAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg5pS56Z2p5Li05bqK6K+V6aqM5py65p6E566h55CG77yM5Yqg5b+r5LiK5biC5a6h5om55a6h5om5ICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDE3LzEyLzEzIHwg6I2v55uR5bGAIHwg44CK5Li05bqK5oCl6ZyA6I2v5ZOB5pyJ5p2h5Lu25om55YeG5LiK5biC55qE5oqA5pyv5oyH5Y2XKOW+geaxguaEj+ingeeovynjgIsgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg5Yqg5b+r5rK755aX5Lil6YeN5Y2x5Y+K55Sf5ZG95LiU5bCa5peg5pyJ5pWI5rK755aX5omL5q6155qE55a+55eF5Yib5paw6I2v5LiK5biCICAgICAgICAgICAgIHwKfCAyMDE4LzQgICAgIHwg5riv5Lqk5omAIHwgMThBIOaIkOeriyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg5omT5byA6J6N6LWE5rig6YGTICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDE4LzcvMjcgIHwg6I2v55uR5bGAIHwg44CK5YWz5LqO6LCD5pW06I2v54mp5Li05bqK6K+V6aqM5a6h6K+E5a6h5om556iL5bqP55qE5YWs5ZGK44CLICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg5bCG6I2v54mp5Li05bqK6K+V6aqM55qE5a6h6K+E5pe26ZmQ5Y6L57yp6IezNjDkuKrlt6XkvZzml6UgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDE4LzEyLzEwIHwg5Yy75L+d5bGAIHwg44CK5YWz5LqO55Sz5oql5oyJ55a+55eF6K+K5pat55u45YWz5YiG57uE5LuY6LS55Zu95a626K+V54K555qE6YCa55+l44CLICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg5pyJ5Yqp5LqO5bu656uL5pu05Yqg56eR5a2m5ZKM5ZCI55CG55qE5Yy75L+d5pSv5LuY5L2T57O7ICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAxOS8xLzEgICB8IOWbveWKoemZoiB8IOOAiuWbveWutue7hOe7h+iNr+WTgembhuS4remHh+i0reWSjOS9v+eUqOivleeCueaWueahiOOAiyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IOacieWKqeS6juWMu+S/neWfuumHkeiFvuesvOaNoum4nyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDE5LzcvMjIgIHwg6K+B55uR5LyaIHwg56eR5Yib5p2/5Yib56uLICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IOaJk+W8gOiejei1hOa4oOmBkyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMC8xLzIyICB8IOiNr+ebkeWxgCB8IOOAiuiNr+WTgeazqOWGjOeuoeeQhuWKnuazleOAi+S/ruiuoueJiOWPkeW4gyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCDmmI7noa7mlrDms6jlhozliIbnsbvvvIzkvJjljJbliqDpgJ/ot6/lvoQgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjAvMi8yNSAgfCDlm73liqHpmaIgfCDjgIrlhbPkuo7mt7HljJbljLvnlpfkv53pmpzliLbluqbmlLnpnannmoTmhI/op4HjgIsgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg56uL5Y+v5oyB57ut55qE5aSa5bGC5qyh5Yy755aX5L+d6Zqc5L2T57O7ICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDIwLzcvOCAgIHwg6I2v55uR5bGAIHwg5Y+R5biDIDMg56eN5Yqg5b+r5LiK5biC5bel5L2c56iL5bqPKOeqgeegtOaAp+ayu+eWl++8jOmZhOadoeS7tuaJueWHhu+8jOS8mOWFiOWuoeivhCkgICAgICAgICAgICAgICAgICAgICAgfCDliqDlv6vlt67lvILljJbliJvmlrDoja/nmoTlrqHor4TlrqHmibkgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMC8xMC8xNCB8IOWMu+S/neWxgCB8IOOAiuWFs+S6juWNsOWPkeWMuuWfn+eCueaVsOazleaAu+minemihOeul+WSjOaMieeXheenjeWIhuWAvOS7mOi0ueivleeCueW3peS9nOaWueahiOeahOmAmuefpeOAiyAgICAgICAgICAgICAgICB8IOaPkOWNh+WMu+S/neWfuumHkeS9v+eUqOaViOeOhyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjAvMTAvMTcgfCDlm73liqHpmaIgfCDjgIrkuK3ljY7kurrmsJHlhbHlkozlm73kuJPliKnms5XjgIsgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IOW7uueri+S6huiNr+WTgeS4k+WIqeS/neaKpOacn+mZkOihpeWBv+WItuW6piAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMS80LzIyICB8IOWMu+S/neWxgCB8IOOAiuWFs+S6juW7uueri+WujOWWhOWbveWutuWMu+S/neiwiOWIpOiNr+WTgeKAnOWPjOmAmumBk+KAneeuoeeQhuacuuWItueahOaMh+WvvOaEj+ingeOAiyAgICAgICAgICAgICAgICAgICAgIHwg5L+d6Zqc5Yy75L+d5ZOB56eN6aG65Yip6JC95ZywICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMS8xMS8xNSB8IOiNr+ebkeWxgCB8IOOAiuS7peS4tOW6iuS7t+WAvOS4uuWvvOWQkeeahOaKl+eZjOiNr+eJqeS4tOW6iueglOWPkeaMh+WvvOWOn+WImeOAiyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCDlh4/lsJHlkIzotKjljJbvvIzov73msYLpq5jku7flgLzliJvmlrAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyMi8yLzIxICB8IOiNr+ebkeWxgCB8IOOAiuiNr+WuoeS4reW/g+WKoOW/q+WIm+aWsOiNr+S4iuW4gueUs+ivt+WuoeivhOW3peS9nOeoi+W6jyjor5XooYwp44CLICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg6L+b5LiA5q2l5LyY5YyW5a6h6K+E5rWB56iLICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDIzLzcvMjEgIHwg5Yy75L+d5bGAIHwg44CK6LCI5Yik6I2v5ZOB57ut57qm6KeE5YiZ44CLICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCDljLvkv53osIjliKTnroDmmJPnu63nuqbpmY3luYXmnInpmZAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjMvOC8yNSAgfCDoja/nm5HlsYAgfCDjgIroja/lk4HpmYTmnaHku7bmibnlh4bkuIrluILnlLPor7flrqHor4TlrqHmibnlt6XkvZznqIvluo8o6K+V6KGMKSjkv67orqLlvoHmsYLmhI/op4HnqL8p44CLICAgICAgICAgICAgICAgfCDpmYTmnaHku7bmibnlh4bmlLbntKfvvIzpvJPlirHlt67lvILljJbliJvmlrAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwKfCAyMDI0LzIvNSAgIHwg5Yy75L+d5bGAIHwg44CK5YWz5LqO5bu656uL5paw5LiK5biC5YyW5a2m6I2v5ZOB6aaW5Y+R5Lu35qC85b2i5oiQ5py65Yi2IOm8k+WKsemrmOi0qOmHj+WPkeWxleeahOmAmuefpe+8iOW+geaxguaEj+ingeeov++8ieOAiyAgICB8IOWHj+aMgeiNr+WTgeS7t+agvOeUseW4guWcuuWGs+WumueahOWfuuacrOWOn+WImSAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8CnwgMjAyNC83LzE1ICB8IOWbveWKoemZoiB8IOOAiuWFqOmTvuadoeaUr+aMgeWIm+aWsOiNr+WPkeWxleWunuaWveaWueahiOOAiyAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCDnu5/nrbnljLvkv53mlK/ku5jjgIHllYbkuJrkv53pmanjgIHoja/lk4HphY3lpIfkvb/nlKjjgIHmipXono3otYTnrYnmlL/nrZYgICAgICAgICAgICAgICB8CnwgMjAyNS8xLzMgICB8IOWbveWKoemZoiB8IOOAiuWFs+S6juWFqOmdoua3seWMluiNr+WTgeWMu+eWl+WZqOaisOebkeeuoeaUuemdqeS/g+i/m+WMu+iNr+S6p+S4mumrmOi0qOmHj+WPkeWxleeahOaEj+ingeOAiyAgICAgICAgICAgICAgICB8IOaPkOWHuuKAnOaJk+mAoOWFt+acieWFqOeQg+ernuS6ieWKm+eahOWIm+aWsOeUn+aAgeKAneeahOaImOeVpeebruaghyAgICAgICAgICAgICAgICAgICAgfAp8IDIwMjUvMS8xNyAgfCDljLvkv53lsYAgfCDmlrDpl7vlj5HluIPkvJogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgfCDmmI7noa7kuKTnsbvnm67lvZXlsIblvJXlr7zmg6DmsJHkv53nrYnllYbkv53kuqflk4Hopobnm5bliJvmlrDoja8gICAgICAgICAgICAgICAgICAgfAoK6LWE5paZ5p2l5rqQ77ya5Yy76I2v6a2U5pa577yM5YW05Lia6K+B5Yi457uP5rWO5LiO6YeR6J6N56CU56m26Zmi5pW055CG
所屬報告： 醫藥生物行業中國創新藥3.0時代：全球競爭力與商業化盈利的雙重驗證-250418（19頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站